SEC Form 4 · accession 0001209191-18-009413
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Heather D Turner
Officer — Former EVP, GC & Sec.
Period of report
Feb 9, 2018
Accepted (ET)
Feb 12, 2018 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 9, 2018 | S | 4,596 | $36.63 | D | 77,112 | D | |
| Common StockF3 | Feb 9, 2018 | S | 4,123 | $37.38 | D | 72,989 | D | |
| Common StockF4 | Feb 9, 2018 | S | 600 | $38.63 | D | 72,389 | D | |
| Common StockF5 | Feb 9, 2018 | S | 733 | $39.66 | D | 71,656 | D | |
| Common StockF6 | Feb 9, 2018 | S | 600 | $40.62 | D | 71,056 | D | |
| Common StockF7 | Feb 9, 2018 | S | 1,562 | $41.69 | D | 69,494 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted September 23, 2016.
- F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $37.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.05 to $38.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $39.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $39.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $41.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.35 to $41.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.